Topic: central nervous system
The collaboration gives Neurocrine a potential source of small molecules to treat disorders of the central nervous system.
Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
VistaGen Therapeutics has licensed Pherin Pharmaceuticals' lead candidate, a nasal spray for social anxiety disorder.
After an aborted attempt earlier this year, Alzheon is having another go at an IPO to help fund new trials of its Alzheimer’s candidate tramiprosate.
Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.
Karuna will start mid-stage trials of a Lilly drug, shelved due to side effects, as part of a combination therapy for schizophrenia later this year.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Alzheon is still trying to build a case for a pivotal trial of its Alzheimer’s candidate and says new data support its plans.
Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
Titan gets the OK to start stage two in a trial of its ropinirole implant for Parkinson’s—but has to postpone because of financial constraints.